Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine.

Vaccine · 2021 · PMC8062787 · PMID 33744044

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

For example, the 2–8 °C RV3-BB stability profile after 24 months showed a trend of 0.0 log 10 FFU/mL loss (with 200 mM adipic acid, F5), 0.1 log 10 FFU/mL loss (with 200 mM sodium succinate, F2), 0.4 log 10 FFU/mL loss (with 400 mM sodium succinate, F3) and 0.5 log 10 FFU/mL loss (with 400 mM sodium acetate, F4).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.